These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 36221119)

  • 1. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
    Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
    J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
    Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
    Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
    Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
    J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.
    Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
    Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
    Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
    Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Trends in Immunotherapy for Adult Sarcomas.
    Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
    Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 12. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments.
    Benesova I; Capkova L; Ozaniak A; Pacas P; Kopeckova K; Galova D; Lischke R; Buchler T; Ozaniak Strizova Z
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):134. PubMed ID: 38493445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
    Bertucci F; Niziers V; de Nonneville A; Finetti P; Mescam L; Mir O; Italiano A; Le Cesne A; Blay JY; Ceccarelli M; Bedognetti D; Birnbaum D; Mamessier E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
    Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
    Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
    Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
    Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
    Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
    BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
    Bertucci F; De Nonneville A; Finetti P; Perrot D; Nilbert M; Italiano A; Le Cesne A; Skubitz KM; Blay JY; Birnbaum D
    Ann Oncol; 2018 Feb; 29(2):459-465. PubMed ID: 29069276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.